济民可信将创新口服AR降解剂全球开发及商业化权益独家许可给基因泰克

2022年8月18日，中国上海。

济民可信集团宣布，集团及旗下子公司上海济煜医药科技有限公司（以下简称“上海济煜”）与罗氏及旗下基因泰克（以下简称“基因泰克”）达成一项独家许可协议，上海济煜将具有自主知识产权的口服雄激素受体（AR）降解剂JMKX002992在全球的开发及商业化权利独家许可给基因泰克。

根据协议，基因泰克将获得JMKX002992在全球范围的独家开发及商业化权利，并承担全部的开发及商业化费用。作为回报，基因泰克将向上海济煜支付6000万美元首付款，并在达到协议约定的里程碑时支付相应的开发和商业化里程碑款项，里程碑款项最高可达5.9亿美元。此外，上海济煜还将获得合作产品基于净销售额的梯度提成。

JMKX002992是由上海济煜小分子创新研究院自主研发的一款全新口服AR降解剂，雄激素受体是公认的前列腺癌疾病驱动因素，JMKX002992对于对现有疗法耐药的前列腺癌患者具有治疗潜力。

济民可信集团总裁梁宏表示：“我们很高兴与罗氏达成合作，罗氏是世界领先的制药企业，我们相信这次合作将加速推进JMKX002992开发，让更多患者受益。这是我们创新药出海的第三个成功案例，我们很欣喜可以在上海研发中心成立四年时间里取得如此成绩。济民可信将持续践行‘济世惠民、信待天下’的企业使命，以创新成果造福更多患者。”

“前列腺癌是全球范围内男性的重要致死因素，”罗氏制药外部合作全球负责人James Sabry表示，“某些类型的前列腺癌治疗特别困难。济民可信开发的创新口服AR降解剂，与罗氏在晚期前列腺癌创新治疗方案的开发方面所做的工作互补。”

▌关于济民可信集团

济民可信集团创建于1999年，总部位于中国南昌，主要产品管线为肾病、肿瘤、心脑血管、呼吸抗感染、疼痛五大领域，致力于为患者提供高质量的药品和创新医药解决方案。作为中国领先的大型现代制药集团之一，济民可信集团已连续多年位列中国医药工业百强前十。

上海济煜医药科技有限公司是济民可信集团的研发中心及全资子公司，致力于成为具有全球影响力的药物研发中心，其研发管线涵盖生物大分子创新药、化学小分子创新药、创新中药、创新制剂及复杂仿制药。当前，小分子创新研究院已有十余个项目进入IND或IND申报准备阶段，三个进入临床阶段。

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

Shanghai, China – Aug. 18, 2022 – Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.

Under the terms of the agreement, Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs. In return, Genentech will pay Jemincare a USD 60 million upfront payment. Jemincare is also entitled to receive up to USD 590 million in additional payments upon achievement of certain development, regulatory and sales-based milestone targets. Jemincare is also entitled to receive tiered royalties on net sales.

JMKX002992 is a novel oral degrader of the androgen receptor, a confirmed disease driver in prostate cancer. JMKX002992 has the potential to treat patients with prostate cancer who have developed resistance to current therapies.

“We are delighted to enter into collaboration with Roche, one of the world’s leading pharmaceutical companies providing transformative innovative solutions across major disease areas, and Genentech, a worldwide leading innovator in oncology. We trust this partnership could significantly enhance and accelerate the development and potential commercialization of JMKX002992 to benefit patients. This is our third innovative therapy partnered globally. We are proud of this achievement within only four years since the establishment of our R&D center. Jemincare will continue to realize our commitment to benefit patients with innovative solutions.” said Mr. Hong Liang, President of Jemincare Pharmaceutical Group.

“Prostate cancer remains a leading cause of death in men worldwide,” said James Sabry, Global Head of Roche Pharma Partnering. “Certain forms of prostate cancer can be particularly difficult to treat. Jemincare’s novel oral androgen receptor degrader will complement our efforts to develop new treatment options for patients with advanced prostate cancer.”

About Jemincare

Jiangxi Jemincare Group Co., Ltd. is a leading pharmaceutical company from China. Founded in 1999, Jemincare is mainly engaged in pharmaceutical industry. The company is dedicated to the development, manufacturing and commercialization of therapeutics in its strategic fields including oncology, nephrology, cerebro-cardiovascular, anti-infection, analgesic, respiratory and Pediatrics. Shanghai Jemincare Pharmaceutical Co., Ltd is the R&D center of Jiangxi Jemincare Group Co., Ltd. Shanghai Jemincare has developed a strong team with around 500 scientists comprised by 3 innovation centers, Small Molecule Innovative Center, Biologics Innovation Center and Technology Innovation Center. The androgen receptor degrader program was developed by the Small Molecule Innovation Center which had more than 10 programs entering IND or IND-enabling stage and 3 programs entering clinical stage. For more information, please visit www.jemincare.com